arrow
B

Brigida Anna Maiorano

irccs sanraffaele hospital
H指数:21
被引数:1,097

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world comparative outcomes of first-line immune combinations (ICI–ICI vs ICI–TKI) in metastatic renal cell carcinoma with sarcomatoid features

晚期肉瘤样特征性肾细胞癌中一线免疫联合疗法(ICI–ICI vs ICI–TKI)的实世界比较结果

2026-10-220
OA
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

奥拉帕利在全球真实世界中对具有同源重组修复改变的转移性去势抵抗性前列腺癌患者的疗效

2026-08-310
OAAI
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study

转移性肾细胞癌一线治疗方案的选择模式:Meet-URO 33—REGAL研究的真实世界分析

2026-08-200
PRE
Correction: Parente et al. Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics 2022, 12, 685

修正:Parente等人. 接受ICI治疗并出现胃肠道毒性的患者的临床、内镜和组织学特征:来自单一机构经验的最新消息和重新评估。Diagnostics 2022, 12, 685

2026-07-290
OA
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials

肌层浸润性膀胱癌围手术期全身治疗比较疗效:随机试验的网络荟萃分析

2026-07-220
OAAI
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study

相对剂量强度对肌肉浸润性尿路上皮癌新辅助化疗中病理完全缓解的影响:一项多中心回顾性研究

2026-07-020
OAAI
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis

avelumab维持治疗晚期尿路上皮癌中系统性炎症标志物的预后价值:多中心SAILOR分析

2026-06-170
OAAI
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy

同源重组缺陷和基因组改变在晚期前列腺癌中的研究:精准治疗的启示

2026-04-010
PRE
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25

转移部位和数量可预测avelumab维持治疗晚期尿路上皮癌的结局:meet-URO 25研究的结果

2026-02-140
OAAI
Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection—Results of the MEET-URO 22 Study

SARS-CoV-2感染后能够维持/恢复持续抗肿瘤治疗的转移性前列腺癌患者的长期肿瘤学结局——MEET-URO 22研究的结果

Cancers
IF4.4
2026-01-150
OAAI
First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysis

BCG-naïve非肌肉浸润性膀胱癌的一线治疗:一项系统评价和Meta分析

2026-01-050
OAAI
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

检查点抑制剂联合卡介苗 (BCG) 治疗初治高危非肌肉浸润性膀胱癌的疗效和安全性: 来自ALBAN、CREST和POTOMAC试验的综合证据

2025-12-310
PRE
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)

Avelumab维持治疗在晚期尿路上皮癌中的真实世界有效性:来自意大利多中心MALVA研究(Meet-URO 25)的结果

2025-12-010
PRE
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE